Oxagen Limited

Summit Corporation Plc

Atopix Therapeutics Limited

Summit Therapeutics Plc

Graham Michael Wynne

Richard Edward Armer

Colin Richard Dorgan

Peter David Johnson

Julia Vile

Olivier De Moor

Richard Storer

Mark Whittaker

Eric Roy Pettipher

Frank Schroer

Francis Xavier Wilson

Stephen Paul Wren

Alan Geoffrey Roach

Paul James Davis

Richard Vickers

Paul Damien Price

Gary Nugent

Richard Joseph Pye

Richard John Vickers

Jonathon Mark Tinsley

Carole Eliane Andree Maillol

Alexander Charles Weymouth-Wilson

Robert Clarkson

Renate Van Well

Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by,

Antibacterial compounds

Compounds of general formula (II) wherein

Compounds having CRTH2 antagonist activity

Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by,. 

Compounds of general formula (I) whereinW is chloro or fluoro;Ris phenyl optionally substituted with one or more substituents, selected from halo, &#x2014;CN, &#x2014;C-Calkyl, &#x2014;SOR, &#x2014;SOR, &#x2014;SON(R), &#x2014;N(R), &#x2014;NRC(O)R, &#x2014;COR, &#x2014;CONRR, &#x2014;NO, &#x2014;OR, &#x2014;SR, &#x2014;O(CH)OR, or &#x2014;O(CH)O(CH)ORwherein

There are disclosed compound of Formula (1): A, A, Aand Awhich may be the same or different, represent N or CR, X is a divalent group selected from O, S(O), C&#x2550;W, NR, NC(&#x2550;O)Rand CRR, W is O, S, NR, Y is N or CR, one of R, R, R, R, Rand NRrepresents -L-R, in which L is a single bond or a linker group, additionally, R, R-R, which may be the same or different, independently represent hydrogen or a substituent and Rrepresents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO, NRR, in which Rand R, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of Rand Rmay represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A-Aeach represent CR, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CRR, Rand R, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia. 

Treatment of Duchenne muscular dystrophy

Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations. 

Drug combinations for the treatment of duchenne muscular dystrophy

Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. 

Provided is a process for the preparation of 5-(ethylsulfonyl)-2-(naphthalen-2-yl) benzo[d] oxazole useful in the treatment of Duchenne muscular dystrophy.

Treatment of duchenne muscular dystrophy

Compounds of general formula (II) whereinW is chloro or fluoro;Ris phenyl optionally substituted with one or more substituents, selected from halo, &#x2014;CN, &#x2014;C-Calkyl, &#x2014;SOR, &#x2014;SOR, &#x2014;SON(R), &#x2014;N(R), &#x2014;NRC(O)R, &#x2014;COR, &#x2014;CONRR, &#x2014;NO, &#x2014;OR, &#x2014;SR, &#x2014;O(CH)OR, or &#x2014;O(CH)O(CH)ORwherein

Growing community of inventors

Abingdon, United Kingdom

Graham Michael Wynne